Skip to main content
. 2024 Mar 27;17:273–290. doi: 10.2147/JAA.S438981

Figure 1.

Figure 1

AER reduction during benralizumab treatment in naïve, bio-experienced, omalizumab, and mepolizumab groups. Any (A) and severe (B) AER are shown at index date and after 48 and 96 weeks of treatment with benralizumab.